Autopsy report · NCT05477485

Antiretroviral Improvement Among Medicaid Enrollees

“Insufficient rate of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 1 year 1 month before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Virginia Commonwealth University

Sponsor type

University, hospital or other

Conditions

Human Immunodeficiency Virus

Interventions

Experimental: AIMS program - patient; No Intervention/Usual care

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
  “Insufficient accrual rate” (98% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (88% match in meaning)
• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
  “Poor accrual rate” (88% match in meaning)
• Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
  “Low accrual rate” (87% match in meaning)
• PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer
  “Insufficient accrual” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.